A Hyperliquid wallet generated about $4.955 million in referral rewards from 81,741 referrals, with nearly all payouts in USDC tokens totaling around $4.94 million. Other stablecoins like USDe, USDT0, and USDH contributed a small combined amount of approximately $14,150. This highlights the wallet's significant referral activity and dominance of USDC in its rewards. The report underscores the growing importance of referral programs in digital asset markets.
The Hyperliquid wallet's referral program generated about $4.955 million from 81,741 referrals, mostly paid in USDC tokens totaling around $4.94 million. For readers following the broader cryptocurrency market, here is Pluang's market snapshot as of Nov 12, 2026 04:22 WIB: out of 50 major cryptocurrencies, 31 rose and 18 fell. Notable movers include EOS at Rp12.649 (+8.13%), AVAX at Rp155.744 (+3.70%) with 81% buy order activity, and FIL at Rp13.938 (+3.60%) with 100% buy order activity and a typical hold time of 101 days.
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
